IRIS Institutional Research Information System - OPENBS Open Archive UniBS

METRA, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 75.814
AS - Asia 49.752
EU - Europa 41.590
SA - Sud America 11.744
AF - Africa 945
OC - Oceania 122
Continente sconosciuto - Info sul continente non disponibili 87
AN - Antartide 2
Totale 180.056
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 74.546
SG - Singapore 16.461
CN - Cina 15.964
UA - Ucraina 10.930
BR - Brasile 10.058
HK - Hong Kong 7.551
IT - Italia 6.446
RU - Federazione Russa 5.155
DE - Germania 4.977
PL - Polonia 3.642
VN - Vietnam 2.823
FI - Finlandia 2.646
GB - Regno Unito 2.372
TR - Turchia 2.293
IE - Irlanda 1.952
IN - India 1.749
FR - Francia 1.334
SE - Svezia 703
BD - Bangladesh 664
AR - Argentina 649
CA - Canada 527
MX - Messico 457
IQ - Iraq 367
ID - Indonesia 317
EC - Ecuador 301
ZA - Sudafrica 297
NL - Olanda 285
AT - Austria 241
JP - Giappone 205
SA - Arabia Saudita 191
PK - Pakistan 179
CO - Colombia 177
ES - Italia 176
VE - Venezuela 147
MA - Marocco 146
PY - Paraguay 134
CZ - Repubblica Ceca 131
UZ - Uzbekistan 128
BE - Belgio 124
KE - Kenya 124
QA - Qatar 118
AU - Australia 112
CL - Cile 98
MU - Mauritius 85
EG - Egitto 81
PE - Perù 78
EU - Europa 76
AE - Emirati Arabi Uniti 74
TN - Tunisia 74
UY - Uruguay 68
IL - Israele 59
NP - Nepal 56
IR - Iran 53
RO - Romania 53
LT - Lituania 52
JO - Giordania 51
KZ - Kazakistan 49
EE - Estonia 47
JM - Giamaica 47
KR - Corea 47
AZ - Azerbaigian 46
MY - Malesia 45
TT - Trinidad e Tobago 44
DZ - Algeria 40
PA - Panama 40
AL - Albania 39
HN - Honduras 38
CH - Svizzera 37
DO - Repubblica Dominicana 36
ET - Etiopia 33
OM - Oman 33
PT - Portogallo 30
NO - Norvegia 29
TW - Taiwan 29
LB - Libano 28
BG - Bulgaria 26
BO - Bolivia 26
PH - Filippine 26
CR - Costa Rica 20
GR - Grecia 20
HU - Ungheria 20
LV - Lettonia 20
TH - Thailandia 20
PS - Palestinian Territory 18
SN - Senegal 18
BH - Bahrain 16
KG - Kirghizistan 16
NG - Nigeria 16
SK - Slovacchia (Repubblica Slovacca) 15
DK - Danimarca 14
MK - Macedonia 13
RS - Serbia 13
BB - Barbados 11
LA - Repubblica Popolare Democratica del Laos 11
LU - Lussemburgo 10
SV - El Salvador 10
XK - ???statistics.table.value.countryCode.XK??? 10
AM - Armenia 9
BA - Bosnia-Erzegovina 9
LK - Sri Lanka 9
Totale 179.890
Salva come PNG Salva come JPEG
Città #
Fairfield 8.127
Jacksonville 7.998
Singapore 7.641
Hong Kong 7.521
Woodbridge 6.023
Ashburn 5.480
Houston 4.170
Chandler 4.079
Moscow 3.832
Beijing 3.597
Cambridge 3.590
Warsaw 3.584
Princeton 3.514
Wilmington 3.437
Ann Arbor 3.254
Seattle 3.103
Nanjing 2.763
Dublin 1.935
New York 1.850
Istanbul 1.829
Los Angeles 1.403
Helsinki 1.082
Ho Chi Minh City 1.038
Nanchang 1.037
Buffalo 927
São Paulo 834
Des Moines 812
The Dalles 777
Milan 682
Shenyang 680
Hebei 661
Redondo Beach 626
Changsha 605
Tianjin 532
Munich 524
Hanoi 522
San Diego 507
Jiaxing 452
Brescia 441
Dallas 439
Jinan 407
Shanghai 384
Dearborn 375
Chicago 367
Rio de Janeiro 329
San Francisco 326
Kunming 318
London 305
Rome 292
Hangzhou 255
Kocaeli 247
Verona 233
Belo Horizonte 230
Romola 221
Nuremberg 209
Brooklyn 181
Santa Clara 179
Tokyo 179
Guangzhou 177
Zhengzhou 174
Mexico City 173
Toronto 173
Turku 171
Boardman 170
Brasília 165
Lancaster 163
Curitiba 153
Lappeenranta 148
Frankfurt am Main 143
Montreal 139
Ningbo 139
Pune 139
Lanzhou 133
Porto Alegre 131
Johannesburg 129
Atlanta 125
Dhaka 122
Salvador 122
Dong Ket 120
Council Bluffs 119
Doha 118
Tashkent 117
Boston 115
Campinas 113
Stockholm 111
Brussels 110
Phoenix 106
Taizhou 106
Vienna 106
Chennai 105
Norwalk 104
Haikou 103
Nairobi 103
Denver 101
Haiphong 101
Baghdad 99
Da Nang 99
Quito 97
Charlotte 93
Orange 91
Totale 112.271
Salva come PNG Salva come JPEG
Nome #
Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis 3.145
Un caso di Sindrome di Bland-White-Garland: origine anomala dell’arteria coronaria sinistra dall’arteria polmonare. 715
Effect of nesiritide in patients with acute decompensated heart failure. 412
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 395
Inodilatatori: perché e quali. 394
American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). 383
Farmaci inotropi non digitalici. 369
Livelli circolanti del marcatore tumorale CA 125 in pazienti con scompenso cardiaco cronico:relazione con la classe NYHA, i parametri ecocardiografici e variazioni indotte dalla terapia. 350
La cardiomioplastica dinamica come trattamento della cardiomiopatia dilatativa ingravescente. 342
Il genotipo DD per il gene dell’enzima di conversione dell’angiotensina identifica i pazienti con insufficienza cardiaca che possono beneficiare di dosi medio elevate di ACE inibitori. 329
Worsening renal function in patients hospitalised for acute heart failure: Clinical implications and prognostic significance 300
Impact of serial troponin release on outcomes in patients with acute heart failure: Analysis from the protect pilot study 272
Can we improve the treatment of congestion in heart failure? 269
The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure 263
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European society of cardiology and endorsed by the European society of intensive care medicine 258
Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. 255
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 253
Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. 250
Old and new intravenous inotropic agents in the treatment of advanced heart failure 248
I polimorfismi Arg16Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca 247
Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? 247
Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. 244
Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. 244
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial 240
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure 240
Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. 232
May 2020 at a glance: ischaemic heart failure and sex-related differences 231
Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study 229
I polimorfismi Arg16 Gly del gene recettore beta-2 adrenergico influenzano i parametri emodinamici e la prognosi dei pazienti con insufficienza cardiaca. 227
Postdischarge assessment after a heart failure hospitalization: the next step forward. 224
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study 221
L’ indice di performance miocardica ( MPI ) è un importante indicatore prognostico nei pazienti affetti da insufficienza cardiaca cronica. 219
Troponin T levels in patients with acute heart failure : clinical and prognostic significance of their delection and release during hospitalisation 218
Highlights of the 2009 scientific sessions of the European Society of Cardiology. 215
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study 215
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. 212
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. 209
Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 202
Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release. 199
Characteristics and mid-term follow-up of a single-center population affected by Tako-Tsubo cardiomyopathy 190
Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents. 189
Task Force sullo Scompenso Cardiaco Acuto della Societa Europea di Cardiologia. Versione italiana a cura di A Gavazzi, M Metra. Riassunto esecutivo delle linee guida sulla diagnosi e trattamento dello scompenso cardiaco acuto. 188
Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction 188
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Societyof Cardiology 187
Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry 187
Sindromi coronariche acute: ruolo dell’infezione cronica da Helicobacter Pylori e Citomegalovirus. 185
Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: A long-term comparison 184
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. 183
Percutaneous edge-to-edge mitral valve repair for the treatment of acute mitral regurgitation complicating myocardial infarction: A single centre experience 183
The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy. 182
Determinazione dell’equilibrio simpato-vagale attraverso l’analisi spettrale della variabilità della frequenza cardiaca in pazienti con insufficienza cardiaca di diverso grado di severità. 180
Mitraclip therapy in patients with functional mitral regurgitation and missing leaflet coaptation: is it still an exclusion criterion? 178
Efficacia di un nuovo diuretico, la muzolimina, in pazienti con insufficienza cardiaca. 177
Self-expanding transcatheter aortic valve implantation for degenerated small Mitroflow bioprosthesis: Early and midterm outcomes 177
Effectiveness of MitraClip therapy in patients with refractory heart failure 176
Fattori di rischio ed “epidemiologia inversa” nei pazienti con insufficienza cardiaca. 175
A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension. 175
Acute heart failure congestion and perfusion status – impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry 172
Amino acids and derivatives, a new treatment of chronic heart failure? 171
Effetti cardiovascolari della ventilazione servo-adattativa (ASV) in pazienti affetti da apnee notturne e scompenso cardiaco cronico con disfunzione sistolica ventricolare sinistra 171
Effects of serelaxin in patients with acute heart failure 171
Effects of the Adenosine A(1) Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure an Renal Dysfunction Results From PROTECT (Placebo-Controlled Randomized Study of the Selective A(1) Adenosine ReceptorAntagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function) 171
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 169
Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results 165
A drastic complex atheromatous aorta. A case report. 164
An unusual case of myocardial infarction 163
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 163
Effects of ivabradine on endothelial function, aortic properties and ventricular-arterial coupling in chronic systolic heart failure patients 162
January 2017 at a glance: oncology, diabetes and antidiabetic treatment, pulmonary hypertension 162
Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry 162
Can we prevent or treat renal dysfunction in acute heart failure? 158
ESC Committe for Practice Guideline (CPG). Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. 158
Global epidemiology of heart failure 156
A case of iatrogenic severe mitral regurgitation 156
Neurohormonal activation in acute heart failure: results from VERITAS 155
Clinical Presentation and Outcome in a Contemporary Cohort of Patients with Acute Myocarditis: The Multicenter Lombardy Registry 155
Effect of High dose of atorvastatin versus moderate dose on endothelial function and inflammatory biomarkers in patients with STEMI 154
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 153
A rationale for the use of BETA-blockers as standard treatment for heart failure 153
Are Beta-1 and alpha2c-adrenergic receptor polymorphisms associated with an increased risk of heart failure in Caucasian subjects: results of a case-control study 153
Is there a rationale for antiplatelet therapy in acute heart failure? 153
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 153
Acute hemodynamic effects of the two dopaminergic agonists ibopamine and dihydroergotamine, a comparison with the parent compound. 151
Raised homocystein plasma concentration in patients with heart failure: Clinical significance 149
Beta- adrenergic receptors polymorphisms and response to CRT 148
Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. 148
EkoSonic Endovascular System for patients with acute pulmonary embolism and contraindication to systemic fibrinolysis 148
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 148
Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure. 147
Prognostic Value of Serial Clinical, Laboratory and Ecocardiographic Tests in Ambulatory Patients with Chronic Heart Failure 147
Endothelial Dysfunction And Vascular Stiffness In Women With A Previous Pregnancy Complicated By Early Or Late Preeclampsia. 147
Different types of tricuspid flail: Case reports and review of the literature 147
High-dose atorvastatin versus moderate dose on early vascular protection after ST-elevation myocardial infarction 147
The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T 146
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. 145
Heart failure in elderly patients: distinctive features and unresolved issues 145
Mineralocorticoid receptor antagonists for heart failure: a real-life observational study 145
Clinical trials update from the World Congress of Cardiology 2006. 144
Angiotensin-converting-enzyme gene polymorphism and heart failure: a case-control study. 144
The puzzle of kidney dysfunction in heart failure: an introduction. 144
Totale 23.664
Salva come PNG Salva come JPEG
Categoria #
all - tutte 973.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 973.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114.513 0 0 0 0 0 2.659 1.089 2.659 3.205 2.018 2.168 715
2021/202211.528 453 2.281 230 766 247 621 378 981 646 1.315 1.114 2.496
2022/202312.157 1.997 251 132 995 1.079 3.563 47 1.195 1.745 107 505 541
2023/202412.855 752 279 742 837 523 1.817 460 472 3.495 340 741 2.397
2024/202533.663 983 971 811 3.719 3.830 2.485 2.772 1.475 2.820 2.920 6.446 4.431
2025/202635.536 5.959 9.470 5.066 9.586 4.792 663 0 0 0 0 0 0
Totale 182.033